New York, NY, July 24, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Oncology Biosimilar Market by Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others), By Drug Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024” . According to the report, global  oncology biosimilar market  was valued approximately USD 2655.19 million in 2017 and is expected to generate revenue of around USD 13,993.64 million by end of 2024, growing at a CAGR of around 26.8% between 2018 and 2024. 

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

Browse through 71 Tables & 15 Figures spread over 110 Pages and in-depth TOC on "Global Oncology Biosimilar Market: By Type, Size, Industry Share, Segments, Analysis and Forecast, 2017 - 2024”.

Request Free Sample Report of Global Oncology Biosimilar Market Report @ https://www.zionmarketresearch.com/sample/onc...lar-market

Oncology biosimilar market is primarily driven by the increased prevalence of cancer, which has led to the increased demand for affordable therapies for the treatment of cancer. There are various pharmaceutical companies available in the markets which are involved in the manufacturing of biosimilar. Patent expiry is also one of the major driving factors for the oncology biosimilar market. Patent expiry will provide an opportunity to the pharmaceutical companies to manufacture more biosimilars which will fuel the market growth in the near future. Increased demand for the healthcare facilities and rapid approval of biosimilars will support the growth of oncology biosimilar market in the near future.    Oncology biosimilar market is segmented on the basis of different types of cancer such as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, and others. On the basis of drug type, the market is segmented into mAb, immunomodulators, hematopoietic agents, G-CSF, and others. G-CSF is expected to grow at the fastest rate in the global market over the forecast period. On the basis of the distribution channel, the market is segmented into retail pharmacies, hospital pharmacy, and online pharmacy. Hospital pharmacy is expected to grow at the fastest rate over the forecast period.

North America is a developed regional market for oncology biosimilar market and is expected to see rapid growth over the forecast period. North America is leading the oncology biosimilar market due to the presence of developed countries such as the U.S., Canada, and others. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the rapid FDA approval process and the increased prevalence of cancer. Furthermore, patent expiration will promote the growth of oncology biosimilar market over the forecast period.

Download Free Report Brochure: https://www.zionmarketresearch.com/requestbro...lar-market

Europe was the second largest regional market in 2017 and is expected to show significant growth in the near future. This growth is mainly due to increased demand for cost-effective therapy for the treatment of cancer.

Asia Pacific is expected to witness significant growth in the near future. In Asia Pacific, China; India; and Japan will continue to be the fastest growing markets in oncology biosimilar market. The growth of Asia Pacific market is expected to be driven by the increased prevalence of cancer in this region and increased demand for cost-effective therapy for the treatment of cancer.

Browse the full  "Oncology Biosimilar Market by Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others), By Drug Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024"  report at  https://www.zionmarketresearch.com/report/onc...lar-market  

In the Middle East & Africa; African region is expected to register noticeable growth due to the increase in cancer patients and increased demand for cost-effective treatment. Latin America is another important regional market and is expected to experience moderate growth over the forecast period. All the above-mentioned factors are expected to fuel the growth of oncology biosimilar market over the forecast period.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/on...lar-market

Some of the key players in oncology biosimilar market include Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD, among others.

Request customized copy of report @ https://www.zionmarketresearch.com/custom/3228   This report segments the global oncology biosimilar market as follows:

Global Oncology Biosimilar Market: Test Type Segment Analysis:

  • Breast Cancer
  • Colorectal Cancer
  • Blood Cancer
  • Neutropenia Cancer
  • Non-Small Cell Lung Cancer 
  • Others

Global Oncology Biosimilar Market: Drug Type Segment Analysis:

  • mAb
  • Immunomodulators
  • Hematopoietic Agents
  • G-CSF 
  • Others

Global Oncology Biosimilar Market: Distribution Channel Analysis:

  • Retail Pharmacies
  • Hospital Pharmacy
  • Online Pharmacy

Global Oncology Biosimilar Market: Regional Analysis:

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research Follow Us Twitter: https://twitter.com/zion_research

Blog: http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

Contact Us:

Joel John 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

Blog: http://zmrblog.com